DG

Deep Genomics

Verified

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. Artificial Intelligence Biotech Healthcare

About Deep Genomics

Deep Genomics is tracked on 100Xfounder as a startup company, founded in 2014, based in Toronto, Ontario, Canada, currently mapped to the Series C stage. Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. Artificial Intelligence Biotech Healthcare

Profile snapshot: Founders linked: Deep Genomics Team. Funding tracked: $180.00M. Hiring focus: Open Roles. Tech tags: AWS, React, Python, and PostgreSQL.

Recent signals:

  • Deep Genomics appears in the 100Xfounder startup directory import feed.

Why it Matters

Deep Genomics is worth tracking because its funding history is already mapped here, including a $180.00M round, the hiring signal points to active work across Open Roles roles, recent coverage is already tied back to this page, and Deep Genomics Team's founder profile is linked directly from the company page. Use this page as the starting point before moving into the company news hub, founder profiles, and related market pages.

Funding Snapshot

Total Funding: $180.00MLast Round: Series C Khosla Ventures, $180M Series C in 2021, $720M valuationAll Rounds: 1
  • Series C | Khosla Ventures, $180M Series C in 2021, $720M valuation

Hiring Roles

This company is actively hiring.

Open Roles

Meet the Founders

Tech Stack

AWSReactPythonPostgreSQL

Last updated: June 1, 2026

Deep Genomics research snapshot

This page is assembled from the published company profile, linked founder directory records, and tagged newsroom context already stored on 100Xfounder. It is most useful as a quick starting point before moving into the deeper company, founder, and hub routes below.

  • Company summary

    Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. Artificial Intelligence Biotech Healthcare

  • Founders covered

    Deep Genomics Team

  • Market position

    Startup | Series C | Toronto, Ontario, Canada

  • Newsroom signal

    No direct company-tagged stories are mapped yet; use the connected hubs below for broader market context.

  • Funding signal

    $180.00M

Best next clicks

Start with the lead founder profile if you want operator context first, then return to the company news hub for chronology.

Related Companies

Alternatives in Startup with comparable market signals.

Discover Now

Newsroom and topic pages connected to Deep Genomics.

No company-specific newsroom stories available yet.

Contextual Research Links

Jump to country, industry, stage, startup taxonomy, and newsroom routes tied to this company.

Want to get featured on 100Xfounder?

Want your company featured with founder details and funding visibility? Start here.

FAQs About Deep Genomics

Common questions people ask about this profile.

What is Deep Genomics?

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. Artificial Intelligence Biotech Healthcare

Who founded Deep Genomics?

Deep Genomics is associated with Deep Genomics Team on 100Xfounder.

Where is Deep Genomics located?

Deep Genomics is listed in Toronto, Ontario, Canada.

What stage is Deep Genomics in?

Deep Genomics is currently mapped to Series C. Funding context: Khosla Ventures, $180M Series C in 2021, $720M valuation

What is the latest funding round of Deep Genomics?

Deep Genomics's latest tracked round is Series C Khosla Ventures, $180M Series C in 2021, $720M valuation. Total tracked rounds: 1.

Is Deep Genomics hiring now?

Deep Genomics hiring status: Open Roles.

What technologies does Deep Genomics use?

Deep Genomics is associated with AWS, React, Python, and PostgreSQL.

Is Deep Genomics verified on 100Xfounder?

Yes. Deep Genomics is currently marked verified on 100Xfounder as of June 1, 2026.

How can users connect with Deep Genomics founders?

Users can move from the company page to any linked founder profiles, review the company news hub, and use listed company links when public contact routes are available.